Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma
- Registration Number
- NCT01234129
- Lead Sponsor
- Instituto Mexicano del Seguro Social
- Brief Summary
Assess the impact in outcome of the use of zoledronic acid in multiple myeloma.
- Detailed Description
Assess if the use of zoledronic acid can improve outcome in patients with multiple myeloma whose are treated with cytoreductive therapy and stem cell transplant.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 320
Diagnosis of multiple myeloma No previous treatment Symptomatic High risk (ISS) or stage III ( Durie-Salmon) No severe comorbidities -
Pregnancy HIV + Refuse treatment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description zoledronic acid zoledronic acid Patients with multiple treated with cytoreductive therapy following by stem cell transplant will be planned to received zoledronic acid zoledronic acid or not zoledronic acid zoledronic acid patients with multiple myeloma will be treated with cytoreductive therapy following by stem cell transplant and did not received zoledronic acid
- Primary Outcome Measures
Name Time Method progression-free disease and overall toxicity in myeloma multiple 3 years In patients treated with cytoreductive therapy following by stem cell transplant and that received zoledronic acid by 2 years,they were evaluable for assess antitumor effect of zoledronic acid
- Secondary Outcome Measures
Name Time Method skeletal event 3 years evaluate the number of skeletal events in patients with multiple myeloma that received zoledronic acid
Trial Locations
- Locations (1)
Tertiary reference oncology center
🇲🇽Mexico, Distrito Federal, Mexico